Evaluation of Albumin/Fibrinogen and C-Reactive Protein/Albumin Ratios as Potential Biomarkers of Systemic Lupus Erythematosus
DOI:
https://doi.org/10.35434/rcmhnaaa.2023.164.2164Keywords:
Systematic Lupus Erythematosus, Diagnosis, Sensitivity, Specificity, Fibrinogen, C-reactive protein, Albumin, Albumin to fibrinogen ratio, C-reactive protein to albumin ratioAbstract
Introduction: C-reactive protein/albumin (CAR) and albumin/fibrinogen (AFR) ratios are novel biomarkers of inflammation that indicate activity status, severity, and response to treatment in systemic lupus erythematosus (SLE); however, the potential value of these ratios in differentiating SLE patients from healthy individuals has not been evaluated. Objective: To evaluate the value of CAR and AFR as potential biomarkers for differentiation of SLE. Material and methods: Analytical case-control study, performed in a SLE group (n=71) and a control group (n=50). Clinical, inflammatory and cardiometabolic parameters with possible diagnostic value (CAR and AFR) were quantified. The diagnostic threshold was estimated by receiver operating characteristic (ROC) curve, sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) for each ratio and 95% confidence intervals. Results: The diagnostic thresholds for AFR and CAR were 13.6 and 0.016, respectively. Sensitivity was 53.53% for AFR and 100% for CAR. The specificity was 98% for AFR and 100% for CAR. The ROC curve showed that CAR had a higher area under the curve (AUC) (AUC=1) compared to AFR (AUC=0.76) statistically significant (p<0.001), according to the AUC values, AFR was considered a favorable biomarker and CAR was considered an excellent biomarker to differentiate SLE. Conclusions: CAR is a biomarker with great potential, low cost and easy to measure, which could improve the sensitivity and specificity to diagnose SLE.
Downloads
Metrics
References
Rees F, Doherty M, Grainge M, Lanyon P, Zhang W, The worldwide incidence and prevalence of systemic lupus erythematosus: a systematic review of epidemiological studies, Rheumatology. 2017 56 (11):945–1961. doi: 10.1093/rheumatology/kex260.
Navarro M, Rodríguez J, Rodríguez J, Vicci H, Pérez-Ybarra L, Crespo G, et al. Factores de riesgo cardiometabólico y biomarcadores de inflamación en pacientes Con Lupus Eritematoso Sistémico. Saber, Universidad de Oriente, Venezuela [Internet]. 2018 [Citado el 20 de diciembre del 2023], 30:488-497. Disponible en: https://www.researchgate.net/publication/328967963_Factores_de_riesgo_cardiometabolico_y_biomarcadores_de_inflamacion_en_pacientes_con_lupus_eritematoso_sistemico
Kiriakidou, M, & Ching, CL. Systemic Lupus Erythematosus. Annals of Internal Medicine. 2020; 172:(11), ITC81–ITC96. doi:10.7326/aitc202006020.
Fanouriakis A, Tziolos N, Bertsias G, Boumpas DT. Update οn the diagnosis and management of systemic lupus erythematosus. Ann Rheum Dis. 2021;80(1):14-25. doi:10.1136/annrheumdis-2020-218272.
Xibillé-Friedmann D, Pérez-Rodríguez M, Carrillo-Vázquez S, Álvarez-Hernández E, Javier F, Ocampo-Torres M, et al. Guía de práctica clínica para el manejo del lupus eritematoso sistémico propuesta por el Colegio Mexicano de Reumatología. Reumatología Clínica, 2019; 15(1): 3-20. doi.org/10.1016/j.reuma.2018.03.011.
Barber MRW, Drenkard C, Falasinnu T, Hoi A, Mak A, Kow NY, et al. Global epidemiology of systemic lupus erythematosus [published correction appears in Nat Rev Rheumatol. Nat Rev Rheumatol. 2021;17(9):515-532. doi:10.1038/s41584-021-00668-1.
Justiz Vaillant AA, Goyal A, Varacallo M. Systemic Lupus Erythematosus [Internet]. StatPearls. Treasure Island (FL): StatPearls Publishing; 2022. PMID: 30571026. [Cited 2023 Jan 30];2-41. Available from: https://www.ncbi.nlm.nih.gov/books/NBK535405/.
Vasquez-Canizares N, Wahezi D, Putterman C. Diagnostic and prognostic tests in systemic lupus erythematosus. Best Pract Res Clin Rheumatol. 2017;31(3):351-363. doi: 10.1016/j.berh.2017.10.002.
Aringer M. EULAR/ACR classification criteria for SLE. Seminars in Arthritis and Rheumatism. 2019;49(3): S14-S17. doi: 10.1016/j.semarthrit.2019.09.009.
Aringer M, Petri M. New classification criteria for systemic lupus erythematosus. Curr Opin Rheumatol. 2020;32(6):590-596. doi: 10.1097/BOR.0000000000000740.
Filártiga María Teresa Martínez de. Nuevos biomarcadores en el Lupus Eritematoso Sistémico: su valor diagnóstico y pronóstico. Rev. párr. reumatol. 2022; 8(1): 51-52. doi: 10.18004/rpr/2022.08.01.51.
Montiel D, Cacace P. Mortalidad y causas de muerte en pacientes con lupus eritematoso sistémico. Rev Parag Reumatol. 2022; 8(1):51-52. doi: 10.18004/rpr/2019.05.02.51-57
Dima A, Jurcut C, Balanescu P, Balanescu E, Badea C, Caraiola S, et al. Clinical significance of serum and urinary interleukin-6 in systemic lupus erythematosus patients. The Egyptian Rheumatologist. 2017;39(1): 1-6. doi: 10.1016/j.ejr.2016.05.005
Alba P. Morbimortalidad en el lupus eritematoso sistémico. Rev. Argent. Reumatol. 2015;26(1):7-8. doi: 10.47196/rar.v26i1.623.
Thong B, Olsen N, Systemic lupus erythematosus diagnosis and management, Rheumatology. 2017; 56: i3–i13. doi: 10.1093/rheumatology/kew401
Tunnicliffe DJ, Singh‐Grewal D, Kim S, Craig JC, Tong A. Diagnosis, Monitoring, and Treatment of Systemic Lupus Erythematosus: A Systematic Review of Clinical Practice Guidelines. Arthritis Care & Research. 2015; 67:1440-1452. doi: 10.1002/acr.22591
Quismorio FP, Quismorio AV. Clinical Application of Serologic Tests, Serum Protein Abnormalities, and Other Clinical Laboratory Tests in Systemic Lupus Erythematosus. En: Wallace DJ, Hahn BH, editores. Dubois’ Lupus Erythematosus and Related Syndromes (Ninth Edition). London:Elsevier. 2019;579-97. doi: 10.1016/B978-0-323-47927-1.00046-3
Abdulrahman, M., Afifi, N., El-Ashry, M. Neutrophil/lymphocyte and platelet/lymphocyte ratios are useful predictors comparable to serum IL6 for disease activity and damage in naive and relapsing patients with lupus nephritis. The Egyptian Rheumatologist. 2020; 42(2):107-112. doi: 10.1016/j.ejr.2019.08.002
Tanriverdi Z, Gungoren F, Tascanov MB, Besli F, Altiparmak IH. Comparing the Diagnostic Value of the C-Reactive Protein to Albumin Ratio With Other Inflammatory Markers in Patients With Stable Angina Pectoris. Angiology. 2020 71(4):360-365. doi: 10.1177/0003319719897490.
Yang W, Zhang W, Ying H, Xu Y, Zhang J, Min Q, Huang b, Lin J, Chen J, Wang X,Two new inflammatory markers associated with disease activity score-28 in patients with rheumatoid arthritis: Albumin to fibrinogen ratio and C-reactive protein to albumin ratio. International Immunopharmacology. 2018; 62:293-298. doi: 10.1016/j.intimp.2018.07.007.
He Y, Tang J, Wu B, Yang B, Ou Q, Lin J. Correlation between albumin to fibrinogen ratio, C-reactive protein to albumin ratio and Th17 cells in patients with rheumatoid arthritis. Clin Chim Acta. 2020;500:149-154. doi: 10.1016/j.cca.2019.10.009.
Tominaga T, Nonaka T, Sumida Y, Hidaka S, Sawai T, Nagayasu T. The C-Reactive Protein to Albumin Ratio as a Predictor of Severe Side Effects of Adjuvant Chemotherapy in Stage III Colorectal Cancer Patients. PLoS ONE. 2016; 11(12): e0167967. doi: 10.1371/journal.pone.0167967
Dai LL, Chen C, Wu J, Cheng JF, He F. The predictive value of fibrinogen-to-albumin ratio in the active, severe active, and poor prognosis of systemic lupus erythematosus: A single-center retrospective study. J Clin Lab Anal. 2022;36(9):e24621. doi: 10.1002/jcla.24621.
Wei-ming Y, Wei-heng Z, Hou-qun Y, Yan-mei X, Jing Z, Qing-hua M, et al. Two new inflammatory markers associated with disease activity score-28 in patients with rheumatoid arthritis: Albumin to fibrinogen ratio and C-reactive protein to albumin ratio. International Immunopharmacology. 2018;62: 293-298. doi: 10.1016/j.intimp.2018.07.007.
Zou Y, Qiao J, Zhu H, et al. Albumin-to-fibrinogen ratio as an independent prognostic parameter in untreated chronic lymphocytic leukemia: a retrospective study of 191 cases. Cancer Res. Treatm. 2019;51:664-671. doi: 10.4143/crt.2018.358
Ronit A, Kirkegaard-Klitbo D, Dohlmann T, Lundgren J, Sabin C, Phillips A, Nordestgaard B, and Afzal S. Plasma Albumin and Incident Cardiovascular Disease. Arteriosclerosis, Thrombosis, and Vascular Biology. 2020; 40:473–482. doi: 10.1161/ATVBAHA.119.313681.
Shimizu, T., Ishizuka, M., Suzuki, T. et al. The Value of the C-Reactive Protein-to-Albumin Ratio is Useful for Predicting Survival of Patients with Child–Pugh Class A Undergoing Liver Resection for Hepatocellular Carcinoma. World J Surg. 2018; 42, 2218–2226 (2018). doi: 10.1007/s00268-017-4446-0.
Santos MJ, Vinagre F, Silva JJ, Gil V, Fonseca JE. Cardiovascular risk profile in systemic lupus erythematosus and rheumatoid arthritis: a comparative study of female patients [Internet]. Acta Reumatol Port [Cited on 2023 Jan 10]. 2010;35(3):325-32. Available from: https://pubmed.ncbi.nlm.nih.gov/20975635/
Wang H, Zhou H, Jiang R, Qian Z, Wang F, Cao L. Globulin, the albumin-to-globulin ratio, and fibrinogen perform well in the diagnosis of Periprosthetic joint infection. BMC Musculoskelet Disord. 2021;22(1):583. doi: 10.1186/s12891-021-04463-7.
Petri M, Orbai AM, Alarcón GS, Gordon C, Merrill JT, Fortin PR, et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum. 2012;64(8):2677-86. doi: 10.1002/art.34473.
Yu H, Nagafuchi Y, Fujio K. Biomarcadores clínicos e inmunológicos para el lupus eritematoso sistémico. Biomoléculas. 2021; 11(7):928. doi: 10.3390/biom11070928.
Navarro M. Velocidad de sedimentación globular: métodos y utilidad clínica. Comunidad y Salud [Internet]. 2019 [Citado el 20 de noviembre del 2023]; 17(2):79-88. Disponible en: http://servicio.bc.uc.edu.ve/fcs/cysv17n2/art09.pdf
Lu S, Liu Z, Zhou X, Wang B, Li F, Ma Y, et al. El índice preoperatorio de proporción de fibrinógeno-albúmina (FARI) es un predictor confiable de pronóstico y sensibilidad a la quimiorradioterapia en pacientes con cáncer de recto localmente avanzado sometidos a cirugía radical después de quimiorradioterapia neoadyuvante. Cáncer Manag Res. 2020;12:8555-8568. doi: 10.2147/CMAR.S273065
Downloads
Published
How to Cite
License
Copyright (c) 2024 Luis Alberto Chanamé Arriola, Luis Pérez-Ybarra, Joanne Aleska Juárez Bendezú , María del Pilar Navarro
This work is licensed under a Creative Commons Attribution 4.0 International License.
